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During the search for a potent antifungal drug, a cell-permeable metabolite was isolated from a soil 
isolate taxonomically identified as Penicillium radicum. The strain was found to be a potent antifungal 
agent. Production conditions of the active compound were optimized and the active compound 
was isolated, purified, characterized and identified as a phosphoinositide 3-kinase (PI3K) inhibitor, 
commonly known as wortmannin (Wtmn). This is very first time we are reporting the production 
of Wtmn from P. radicum. In addition to its previously discovered anticancer properties, the broad 
spectrum antifungal property of Wtmn was re-confirmed using various fungal strains. Virtual 
screening was performed through molecular docking studies against potential antifungal targets, and 
it was found that Wtmn was predicted to impede the actions of these targets more efficiently than 
known antifungal compounds such as voriconazole and nikkomycin i.e. 1) mevalonate-5-diphosphate 
decarboxylase (1FI4), responsible for sterol/isoprenoid biosynthesis; 2) exocyst complex component 
SEC3 (3A58) where Rho- and phosphoinositide-dependent localization is present and 3) Kre2p/
Mnt1p a Golgi alpha1,2-mannosyltransferase (1S4N) involved in the biosynthesis of yeast cell wall 
glycoproteins). We conclude that Wtmn produced from P. radicum is a promising lead compound 
which could be potentially used as an efficient antifungal drug in the near future after appropriate 
structural modifications to reduce toxicity and improve stability.
The need for safe and effective antifungal drugs has increased in parallel with the expansion of immu-
nocompromised patients at risk for fungal infections, along with the emergence of multi-resistant fungal 
strains all over the world. The targets of the currently available antifungal compounds are also found in 
mammalian cells, which leads to toxicity and/or adverse drug interaction in the host. The major limita-
tions associated with currently used antifungal compounds are low efficacy rate and severe side effects. 
Thus, it is imperative to expedite the search for a potent antifungal compound which must be non-toxic 
to mammalian cells and can be employed as an alternative for classical antifungal drugs1.
Previous findings reported that several fungal strains are capable of producing narrow to broad 
spectrum antifungal metabolites e.g., Penicillium radicum, Rhizoctonia solani, Fusarium oxysporum, 
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Phytophthora cinnamomi, Pleiochaeta setosa, Plasmodiophora brassicae, Verticillium dahliae, Pythium 
ultimum, Sclerotium rolfsii etc. An earlier report showed that P. radicum can be used as an effective fun-
gicide2. Penicillium spp. have ubiquitous occurrence in diverse ecological niches and they demonstrate 
some important functional attributes associated with plant growth, such as, solubilisation of phosphorus, 
biological control of root diseases and phytohormone production3. Several metabolites from Penicillium 
spp., such as paxisterol and compactin, have been reported for analgesic and antifungal properties in 
animals4.
The most common fungal pathogens for humans continue to be the species of Candida and Aspergillus. 
For many years, the treatment of invasive fungal infections was limited to amphotericin B. Afterwards, 
two triazoles (voriconazole and posaconazole) and three echinocandins (anidulafungin, caspofungin and 
micafungin) have been mostly used for the treatment of fungal infections5. Emergence of resistance and a 
high mortality rate in candidiasis and aspergillosis warrants for discovery of new antifungal drug targets 
or strategies or agents in antifungal therapy.
Wortmannin (Wtmn), a cell-permeable fungal metabolite, has been identified as a potent, selective 
and irreversible inhibitor (IC50 = 4.2 nM) of phosphatidylinositol 3-kinase (PI3K)6. There is evidence of 
the involvement of PI3K in several intracellular signaling pathways, like Toll-like receptor (TLR) sign-
aling7. Inhibition of PI3K with Wtmn enhances TLR-mediated inducible nitric-oxide synthase (iNOS) 
expression, activates NF-κ B and up-regulates cytokine mRNA production8. Also, PI3K is required for 
autophagy9. Autophagy is a complex pathway in which cell material can be sequestered and delivered 
to the lysosome for degradation. Inhibition of PI3K with Wtmn can inhibit autophagic sequestration9. 
Wtmn is a potent anti-cancer drug which failed clinical trials due to problems related to toxicity, solubil-
ity, and stability10. Subsequently, it was re-formulated as a nano-particle to solve all the above mentioned 
issues that earlier caused its failure11. Earlier reports also suggested that slight structural modifications 
in Wtmn distant from the furan ring had little or no effect on its in-vitro efficacy12, this finding opened 
the door for the commercial use of Wtmn and its analogues in medical applications and warrants for 
conformational/interaction understanding of the compound.
Molecular docking plays an important role in structure-based drug designing, functional sites predic-
tion on protein molecular surfaces, protein ligand docking etc13,14. Molecular docking attempts to pre-
dict the binding mode by evaluating the energy scores of different bound conformations with a scoring 
function. Ligand-binding sites are among the most promising targets for drug candidates, whose actions 
depend upon the inhibition or regulation of the target protein functions. Ligand based methods use the 
shape similarity concept while the structure based methods rely on scoring functions i.e., reverse/inverse 
docking against a panel of targets15.
To the best of our knowledge, isolation of Wtmn from Penicillium radicum has not been reported 
earlier (STN search by SciFinder). In the present study, we describe the isolation, identification, charac-
terization, and antifungal and anticancer activities of Wtmn from P. radicum isolated from a soil sample 
collected from agricultural field of northern India. Also, in-silico molecular docking studies have been 
done to predict the possible antifungal targets for the active metabolite.
Results and Discussion
Producer organism and fermentation profile. On the basis of morphological, cultural and phys-
iological characteristics, the isolated strain was found to be closely related to ascomycetes (Table 1 and 
Fig. 1). This fungal strain was designated as SF and further identified on the basis of 18S rRNA homology 
studies and the sequence was submitted in the GenBank under accession no. KJ528407. A partial 18S 
rRNA gene sequence (1112 bp in length) of SF was compared with the sequences already available in 
the GenBank database through BLAST analysis and found to possess close similarity to some members 
of the class ascomycetes, like, Penicillium radicum (DQ891400.1), P. radicum (AY256855.1), P. variablie 
(AY3739393.1), P. islandicum (L14504.1) and Penicillium sp. Re 011124 (AB 080726.1) (Fig. 1). Finally, 
the neighbour-joining phylogenetic tree of the partial 18S rRNA sequence data confirmed that P. radi-
cum (DQ891400.1) was most closely related to the strain SF with 100% sequence similarity (Fig.  1). 
Olive-green in coloured ellipsoidal conidia with roughened or spiral-striated walls (5 × 3.75 μ m) were 
observed under scanning electron microscope (Supplementary Information: Figure SI1). The strain was 
submitted in Microbial Type Culture Collection (MTCC), Institute of Microbial Technology (IMTECH) 
(www.http://mtcc.imtech.res.in), Chandigarh, Punjab, India as Penicillium radicum MTCC 7584.
The growth and fermentation profile of SF (P. radicum) was evaluated in Potato dextrose broth (PDB) 
medium and results have been summarized in Fig. 2. The log phase was observed between 20–48 h and 
maximum biomass (5.5 g/L) was found at 48 h of the fungal growth. The production of the antifungal 
metabolite commenced in the late log phase of the fungal growth and accumulated maximum (110 mg/L) 
in the stationary phase (approximately 120 h of the incubation) and decreased slowly, afterwards. The pH 
of the production medium decreased slightly during the growth of the fungus, whereas in the production 
phase it was increased from 4.0 to 5.5, which suggests that the extracellular metabolites formed during 
the late log phase might be of basic nature, hence increased the pH of the medium.
Purification and chemical characterization of the active compound. The antibiotic (crude) 
productivity purified through gradient elution with silica gel column (liquid-liquid extraction) was 
500 mg/L. The fractions showing antifungal activity were pooled together (185 mg) and again subjected 
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to silica gel column chromatography. Finally, the active fractions were subjected to high performance liq-
uid chromatography (HPLC) to confirm the purity of the active compound (Supplementary Information: 
Figure SI2). The active compound (approximately 88% pure) was eluted at 11.74 min as mentioned in 
the material and methods section (Supplementary Information; Figure SI2). Overall, 110 mg of SF-1 
(active compound) was recovered from the supernatant of 1L fermented culture. The active compound 
constituted about 22% of the ‘crude’ obtained from P. radicum.
The crystals of the purified antifungal compound were ‘off-white’ in color and decomposed at 240–
241 °C. The powder of the purified compound was hygroscopic and very sensitive towards light. When 
stored under sealed and moisture free condition at − 20 °C, it remained active for 4–6 months. The sol-
ubility of the active compound was in the order of these solvents, i.e., CHCl3 > ethyl acetate > MeOH 
> acetonitrile. The molecular formula determined through elemental analysis was found to be C23H24O8 
(data not shown). It was further confirmed by electrospray ionization mass spectrometry (ESI-MS), 1H 
and 13C nuclear magnetic resonance (NMR). ESI-MS analysis showed an intense ion peaks at m/z 451 
(M + Na+) and 879 (2M+ Na+) and revealed that the molecular weight of the compound was 428 
(Supplementary Information; Figure SI3). The UV/visual absorption spectrum showed an intense band 
at λ = 205 nm due to π → π * or n→ π * transition (Supplementary Information; Figure SI4). The band 
S. No. Physiological properties Response
1 Growth on different medium
Glycerol Nitrate Agar (GNA) Thin light brown, conidia absent
 Malt Extract Agar (MEA) light yellow with yel-lowish green conidia
Potato Dextrose Agar (PDA) Olive green with olive green conidia
Czapek’s Dox + Yeast Extract 
Agar (CYA)
Floccose, bright yellow 
with greenish yellow 
conidia
Sabouraud Dextrose Agar 
(SDA)
Floccose, white with 
yellowish conidia
Corn Meal Agar (CMA)
Floccose, pale white 
with dark yellow 
conidia
Oat Meal Agar (OMA) Thin mat like light brown, conidia absent
Glucose-yeast extract-malt 
extract (GYM) Agar
Velutinous, cream 
coloured with dirty 
yellow conidia
2 Enzyme production
Urease Positive
Protease Positive
Tyrosinase Positive
Amylase Positive
Chitinase Negative
Esterase Positive
Lipase Negative
3. Citrate utilization Negative
4. Milk coagulation Positive
5. Sensitivity for antifungal drugs
Kt100 R
Ap100 R
Ns100 R
It100 R
Fu100 R
Ec100 S
Mc100 S
Table 1.  Biochemical properties of the isolated strain. Note: Kt: Ketoconazole; Ap: Amphotericin B; Ns: 
Nystatin; It: Itraconozole; Fu: Fluconzole; Ec: Econazole-nitrate; Mc: Miconazole.
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pattern of the isolated compound (λ = 205, 256 and 292 nm) showed similarity to polyene compounds 
and suggested a polyene nature of the antifungal compound16 (Supplementary Information; Figure SI4). 
The presence of the ether (1215 and 1,230), ester (1,745 and 1,750) and carbonyl (1,675 and 1,680) 
groups in the chemical structure of the compound was confirmed by its Infrared (IR) spectrum (KBr)17 
(Supplementary Information; Figure SI3).
13C NMR (δ ) ppm; 1H NMR (δ ) ppm (multiplicity, J) (Supplementary Information; Figure SI5 & Table 
S1) : C1CH 88.518; 4.76 (dd, 1.83, 6.96), C2 CH2 72.870 ; HA: 3.46 (dd, 1.95. 11.23) HB: 3.01 ( dd,7.01, 
11.09), C3 CO 127.569, C4 C 114.276, C5 C 142.853, C6 C 144.777, C7 O 172.628, C8 C 140.371, C9 C 
149.550, C10 C 40.758 , C11 CH 70.060; 6.16 ( ddd, 2.77, 7.53, 8.93), C12 CH2 36.153; HA: 2.59 (m) HB: 
1.60 ( dd,8.7, 12.8), C13 C 49.181, C14 CH 44.080; 2.89 (ddd, 2.66, 5.97, 12.68), C15 CH2 22.926; HA: 3.17 
(m) HB: 2.06 (m), C16 CH2 35.710; HA: 2.59 (m) HB: 2.26 (m); C17 CO 216.150, C18 CH3 14.564; 0.97 (s), 
Figure 1. Phylogenetic relationship between Penicillium radicum [SF] and other Penicillium sp. 2. 
Figure 2. Fermentation profile of Penicillium radicum. 
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C19 CH3 26.492; 1.74 (s), C20 CH 149.970; 8.25 (s), C21 CO 169.482, C22 CH 21.017; 2.14 (s), C23 CH 
59.437; 3.19 (s).
A search with the spectroscopic data (1H, 13C-NMR, HMBS, HSQC and H2BC) in AntiBase [A 
natural products database for rapid structure determination. Chemical Concepts, Weinheim, Germany 
(2000)] showed similarity with PI3K inhibitor, Wtmn. The structure was finally confirmed by comparing 
13C and 1H-NMR data (Supplementary Information; Figure SI5 & Table SI1) with the literature18 and 
it was found to be identical with Wtmn. Wtmn is a hydrophobic estrogen-related metabolite and the 
production of Wtmn has been reported earlier in Talaomyces/ Penicillium wortmannii, Penicillium funicu-
losum, Myrothecium roridum and Fusarium oxysporum19–23. The chemical structure of Wtmn was similar 
to the structure deposited at PubChem compound database under CID [312145], which was further used 
for in silico antifungal target prediction studies.
Bioactivity of the active compound. The purified active compound obtained from SF culture 
was established as Wtmn. Earlier, Brian et al. (1957) observed the antifungal activity of Wtmn against 
thirty-eight fungal species (Acrosialagmus cinnabarinus, Alternaria sp., Aspergillus claoatus, A. Flavus, A. 
terreus, A. niger, A. Sydowi, Botrytis allii, B. cinerea, B. fabae, Cladosporium herbarum, Rhizopus stoloni-
fer, Cephalosporium acremonium, Fusarium bulbigenum, F. graminearum, Stachybotrys atra, Stemphylium 
sp.) and found strong activity against five species (Botrytis allii, B. cinerea, B. fabae, Cladosporium her-
barum and Rhizopus stolonifer)19. However, in the present study, we extended the bioactivity profile 
of Wtmn by testing the antifungal property against various strains of Candida, Cryptococcus terreus, 
Trichophyton rubrum, Rhizoctonia oryzae, Aspergillus versicolor, Aspergillus fumigates, Aureobasidium 
pullulans, Fusarium moniliforme, and Saccharomyces cerevisiae.
Previous findings reported that the members of Eurotiales of class Eurotiomycetes and hypocreales 
of Sordariomycetes of ascomycota division of fungal kingdom are capable of producing Wtmn. Among 
four reported Wtmn producers19–23, two Talaromyces wortmannii and Penicillium funiculosum belong to 
Trichocomaceae family. Talaromyces funiculosus is the anamorph of Penicillium funiculosum. Talaromyces 
species and most species of Penicillium subgenus Biverticillium reside in a monophyletic clad distant 
from species of other subgenera of Penicillium24. Penicillium radicum is also reported to belong to the 
subgenus Biverticillium and has affinities with P. variabile, P. allahabadense and Talaromyces wortmannii, 
but can be distinguished by differences in morphology, secondary metabolite profiles and unique DNA 
banding patterns25. However, it may be possible that horizontal gene transfer from Talaromyces wort-
mannii which is the first known producer of Wtmn to P. funiculosum and P. radicum is responsible for 
Wtmn production.
The broad spectrum antifungal activity of Wtmn was re-confirmed against 18 different unicellular 
as well as filamentous fungal strains and it was found that Wtmn demonstrated excellent antifungal 
activities. The detailed findings of antifungal screening have been given in Table 2. Wtmn’s MIC value 
Antifungal drugs MIC ± SD (μg/ml)
S. No. Test strain Wtmn Amphotericin B Fluconazole
1 Candida albicans ATCC 24433 0.39 ± 0.05 0.39 ± 0.02 6.25 ± 0.44
2 Candida albicans ATCC 10231 3.13 ± 0.44 1.56 ± 0.11 10.2 ± 0.72
3 Candida albicans ATCC18804 1.56 ± 0.22 1.56 ± 0.11 12.5 ± 0.88
4 Candida albicans ATCC 2091 12.5 ± 1.76 1.56 ± 0.11 25 ± 1.76
5 Candida albicans ATCC 90028 1.56 ± 0.22 1.56 ± 0.11 12.5 ± 0.88
6 Candida tropicalis ATCC 750 12.5 ± 1.76 6.25 ± 0.44 25 ± 1.76
7 Cryptococcus terreus ATCC 11799 1.56 ± 0.22 12.5 ± 0.88 12.5 ± 0.88
8 Trichophyton rubrum ATCC 296 1.56 ± 0.22 3.13 ± 0.22 6.25 ± 0.44
9 Alternaria alternata ATCC 6663 3.13 ± 0.44 3.13 ± 0.22 6.25 ± 0.44
10 Rhizoctonia oryzae ATCC 52545 0.78 ± 0.11 2.5 ± 0.17 5.0 ± 0.35
11 Aspergillus terreus DSM 826 10 ± 1.41 1.25 ± 0.08 12.5 ± 0.88
12 Aspergillus versicolor DSM 1943 0.5 ± 0.07 1.25 ± 0.08 10 ± 0.70
13 Aspergillus niger DSM 2182 12.5 ± 1.76 2.5 ± 0.17 12.5 ± 0.88
14 Aspergillus niger DSM 63263 25 ± 3.53 5.0 ± 0.35 12.5 ± 0.88
15 Aspergillus fumigates ATCC 204305 3.13 ± 0.44 3.13 ± 0.22 6.25 ± 0.44
16 Aureobasidium pullulans DSM 2404 10 ± 1.41 5.0 ± 0.35 12.5 ± 0.88
17 Fusarium moniliforme ATCC 14164 5.0 ± 0.70 5.0 ± 0.35 25 ± 1.76
18 Saccharomyces cerevisiae ATCC 2365 1.56 ± 0.22 1.56 ± 0.11 6.25 ± 0.44
Table 2.  Antifungal activity of Wtmn isolated from Penicillium radicum MTCC 7584.
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spanned a relatively wide range for both unicellular and filamentous fungi ranging from 0.39 μ g/ml (for 
C. albicans ATCC 24433) to 25 μ g/ml (for A. niger DSM 2182). Wtmn showed either better or equivalent 
and in minor cases modest antifungal activities in comparison to other commercially available antifungal 
drugs (amphotericin B and fluconazole) against 18 fungal strains as mentioned in the Table 2.
Earlier in-vitro studies reported that Wtmn has good anticancer activity26, though its clinical use for 
anticancer chemotherapy is restricted due to its toxicity and low stability of the furan ring in solutions12. 
On the similar lines, the cytotoxic activity of the isolated Wtmn was evaluated against four human 
tumor cell lines under in-vitro conditions (Table 3). The cytotoxicity assay showed that the most sensi-
tive lines were HCT-15 and 502713 colon carcinoma and they showed 75 and 90% inhibition at Wtmn 
concentrations of 10 and 30 μ g/ml, respectively. Generally, Wtmn showed modest activity in low passage 
human breast cancer cell lines. Wtmn was capable of inhibiting about 52% of HEP-2 liver carcinoma 
at higher concentrations (30 μ g/ml). Interestingly, IMR-32 neuroblastoma cells were fully insensitive to 
Wtmn (Table 3).
The in-vivo anti-inflammatory and immunosuppressive effects of Wtmn suggested that it has a poten-
tial to work as an inhibitor of signal transduction pathways. Wtmn interacts with many biological targets, 
but binds in-vitro most strongly to PI3K12. Wtmn’s electrophilic 21-site makes a covalent linkage with the 
enzyme and the inhibition of PI3K is irreversible12. The PI3K enzyme is part of a signalling cascade that 
is essential for cell growth and differentiation, therefore Wtmn is a potent antiproliferative agent. Despite 
the toxicity issues, the nanomolar level inhibition of PI3K by Wtmn has inspired numerous synthetic and 
biological studies for its modification as low toxic lead compound12.
Antifungal target prediction for Wtmn. Wtmn is known to interact with many biological targets, 
such as PI3K, mammalian Polo like kinase (PLK1), and serine/threonine kinases of the PI3K family, 
and has been shown to have biological activity, including antifungal and anti-inflammatory properties12. 
Selectivity and excessive toxicity is the major obstacle in the in-vivo clinical use of Wtmn. However, pre-
vious findings suggested that slight structural changes in Wtmn has no major effect on its efficacy and 
prompted us to conduct antifungal target site prediction studies via molecular docking for structural and 
conformational understanding which can be exploited for lead development.
Interactions of Wtmn with the targets of cancerous cells have been studied very well but its interac-
tions with antifungal targets have not been studied yet. Thus, to elucidate these unexplored ‘interactions’, 
virtual screening was performed through in silico molecular docking studies for the prediction of the 
target sites for Wtmn. For this, Wtmn was compared with the previously known potential antifungal 
compounds that can bind to the active site of proteins, thus, obstructing the activities of pathogenicity. 
The structural changes in proteins are responsible for various biological functions and keeping this fact 
in view, the antifungal potential of Wtmn was examined through its interaction with the target proteins. 
Investigations on the atomic and residual properties of the isolated Wtmn and other protein molecules 
used in the present study were retrieved with the help of dedicated software programs. The in silico anal-
ysis showed that the structure of Wtmn perfectly bound with the active sites of known predicted target 
proteins, viz. 1FI4, 1S4N and 3A58, and was then compared with the binding of other known antifungal 
compounds, like, voriconazole, nikkomycin, and pyridobenzimidazole (Table 4). 1FI4 is responsible for 
sterol/isoprenoid biosynthesis, 3A58 where Rho- and phosphoinositide-dependent localization is present 
and 1S4N is involved in the biosynthesis of yeast cell walls glycoproteins27–29. Our antifungal docking 
studies demonstrated that Wtmn bound more effectively with above mentioned targets than the known 
antifungal compounds, i.e., voriconazole and nikkomycin.
Cell lines
 Liver Neuroblastoma Colon
HEP-2 IMR-32 HCT-15 502713
Compounds
Concentration 
(μg/ml) Growth inhibition (%) ± SD
SF (Wtmn) 10 49 ± 0.71 − 74 ± 1.41 76 ± 1.41
SF (Wtmn) 30 52 ± 1.41 − 91 ± 2.12 89 ± 2.82
Actinomycin D 10 66 ± 2.83 68 ± 0.71 70 ± 0.71 69 ± 0.71
Actinomycin D 30 82 ± 1.41 87 ± 0.71 72 ± 1.76 98 ± 2.12
Mito-C 3.34 82 ± 0.71 87 ± 0.71 − 86 ± 2.47
Adriamycin 0.54 79 ± 0.71 89 ± 1.41 − 22 ± 2.12
5-Fu 6.12 − − 27 ± 1.41 15 ± 2.12
Table 3.  Cytotoxic activity of various compounds against various cancerous cell lines. Note: (− ): No 
activity
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The comparative studies of interactions of known antifungal compounds under consideration and 
Wtmn with the above predicted targets were performed on the basis of several energies, namely docking 
energy, intermolecular energy, torsional energy, root mean square (RMS) and internal energy and it was 
found that the docking energies of Wtmn were greater than the known antifungal compounds (Table 5). 
In protein-compound interactions, the lower the docking energy, the higher the binding affinity. The 
binding free energy evaluation by AutoDock (open source software program AutoDock 4.2) includes 
intermolecular energy (van der Waals energy, hydrogen bonding energy, desolvation energy, and elec-
trostatic energy), internal energy and torsional energy. The first two items build up docking energy; the 
first and third items compose binding energy. During in silico analysis the difference in the binding free 
S. 
No. CID No
Antifun-
gal Drugs
Molecular 
Formula IUPAC Name
M.W. 
(g/
mol) Structure
1 312145* Wortman-nin C23H24O8
(1S,6bR,9aS,11R,11bR)-
9a,11b-dimethyl-1-[(methy-
loxy)methyl]-3,6,9-trioxo-
1,6,6b,7,8,9,9a,10,11,11b-
decahydro-3H-furo[4,3,2-de]
indeno[4,5-h]isochromen-11-yl 
acetate
428.43
2 71616* Voricona-zole C16H14F3N5O
(2R,3S)-2-(2,4-difluorophenyl)-
3-(5-fluoropyrimidin-4-yl)-1-
(1,2,4-triazol-1-yl)butan-2-ol
349.31
3 456557* Nikkomy-cin z C20H25N5O10
(2S)-2-[[2s,3s,4s) -2-amino-
4-hydroxy-4-(5-hydroxypyri-
din-2-yl)-3-methylbutanoyl]
amino]-2-[(2R,3S,4R,5R)-5-(2,4-
dioxopyrimidin-1-yl)-3,4-di-
hydroxyoxolan-2-yl]acetic acid
495.44
4 1177777**
Pyrido-
benzimi-
dazole
C21H29N5
1-[2-(diethylamino)ethylami-
no]-2-ethyl-3-methyl 1,5dihy-
dro-pyrido[1,2-a]benzimida-
zole-4-carbonitrile
351 
Table 4.  Various drugs used in the in-silico docking studies. *Adopted from online PubChem database 
(accessed on 07.01.2014). **Adopted from online CHEMBL database (accessed on 13.11.2013).
PDB ID Antifungal compounds
Binding en-
ergy (kcal/
mol)
Docked en-
ergy (kcal/
mol)
Internal en-
ergy (kcal/
mol)
Intermolecular energy 
(kcal/mol)
Torsional 
energy (kcal/
mol)
RMSD 
(Å)
1FI4 Wortmannin − 6.01 − 7.69 − 0.44 − 7.25 1.25 65.866 
Voriconazole − 4.88 − 5.73 0.70 − 6.43 1.56 60.273
Nikkomycin − 3.43 − 6.27 − 0.04 − 6.23 2.80 63.640
pyridobenzimidazole − 7.88 − 10.24 − 0.18 − 10.06 2.18 67.175
1S4N Wortmannin − 7.28 − 8.86 − 0.34 − 8.53 1.25 72.258
Voriconazole − 5.22 − 5.67 1.11 − 6.78 1.56 75.792
Nikkomycin − 4.83 − 7.79 − 0.15 − 7.63 2.80 73.499
pyridobenzimidazole − 19.81 − 22.36 − 0.37 − 21.99 2.18 76.745
3A58 Wortmannin − 5.48 − 6.70 0.02 − 6.73 1.25 67.693
Voriconazole − 6.29 − 6.34 1.56 − 7.85 1.56 89.860
Nikkomycin − 3.06 − 5.89 − 0.03 − 5.86 2.81 83.461
pyridobenzimidazole − 5.83 − 8.41 − 0.40 − 8.01 2.18 85.983
Table 5.  The interaction energies (kcal/mol) of antifungal compounds with protein using AutoDock.
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energy of three different classes of inhibitors provides further insights into their binding mode with 
protein structure. Our in silico docking results demonstrated that Wtmn was energetically favoured over 
voriconazole for all three predicted target proteins, while pyridobenzimidazole was highly favoured for 
the target protein IS4N and slightly better for the other two targets i.e., 1FI4 & 3A58 (Table 5).
Docking studies showed that the amino acid residues of enzyme 1FI4, viz. THR262, SER258, MSE255, 
VAL229 and LEU221 were observed to play an active role in the interaction with Wtmn. However, it is 
a known target site for antifungal compound voriconazole where amino acid residues ASP205, ALA303, 
GLY304, ASP201, GLY112, SER207 were found to be active. Likewise, the in silico analysis also showed 
that 1S4N amino acid residues, such as, SER382, TYR380, HIS379, ILE378, LEU431, GLN429 were active 
with Wtmn, whereas ASP383, HIS379, GLU396, TYR426, LEU431, SER382 were active against pyrido-
benzimidazole, which is a well-known compound of this predicted target site. Similarly, for 3A58 the 
active amino acid residues for Wtmn were GLU103, ASP98, CYS93, LYS100, ASN106 whereas ARG96, 
PRO105, GLU103, ASP98, ILE166, CYS92, ASP98 were active against nikkomycin (Table  6). Due to 
the presence of these interactions with these active amino acid residues, Wtmn worked more efficiently 
than the existing antifungal compounds studied in the present computational study. The computational 
docking technique has already been successfully used in predicting targets for the development of drug 
against KAS II of Mycobacterium tuberculosis H37Rv30 and virulent proteins (aerolysin and hemoly-
sin) of Aeromonas hydrophila31,32. Our docking study also revealed that amino acid residues, SER258 
and ALA303 of 1FI4 play an active role during interaction with Wtmn and known antifungal drug 
voriconazole (Fig.  3). Similarly, the amino acid residues SER382, TYR380 for Wtmn and SER382 for 
Pyridobenzimidazole were active during interaction with the 1S4N (Fig. 3); and those involved in inter-
action with 3A58 were ASN106, CYS93 for Wtmn and ARG96, CYS93 against nikkomycin (Fig. 4). No 
hydrogen bond was formed between those compounds as high interaction energy was observed. Earlier, 
the active amino acids’ residues were reported to be targeted with varied drugs to inhibit DNA ligase 
of M. tuberculosis33, oligomerization in A. hydrophila34, through robust binding affinity between protein 
and drug interactions. The twenty five docking conformations for each ligand were divided into separate 
conformational clusters according to 2 Ǻ RMSD criteria. AutoDock ranked each conformational cluster 
by binding free energy evaluation to find the best binding mode35. Best ranking conformational clusters 
from each class of ligand were further docked using FlexiDock (Licenced version software program) 
module in SYBYL-X (SYBYL X. Tripos International 1699 South Hanley Rd; St.Louis, Missouri, 63144, 
USA) and have been shown in Table 7. Results from AutoDock and FlexiDock showed agreement with 
less than 2 Ǻ RMSD deviations in the conformation of docked ligands (Fig. 3). We have examined the 
mobility of the inhibitors in the active site through 1ns (1000 ps) MD simulation. This was done by calcu-
lating the RMSD of inhibitors atom position to antifungal backbone for all the three systems under con-
sideration. A comparison of RMSD deviation and subsequent conformational changes indicated binding 
mobility in all the three groups of inhibitor.
For pyridobenzimidazole, in the first 450 ps of simulation, the inhibitor aligned itself to a more hori-
zontal position and subsequently loosens contact with catalytic dyad subsite resulting in opening up 
of active site cleft (Fig.  4b). However, about halfway through the simulation inhibitor anchored again 
itself to a catalytic dyad. This occurred by anchoring with the side chains of Asp383 and His379 and 
finally closing the active site. This conformation gradually stabilized at about 800 ps with slight changes 
in the backbone structure. For voriconazole, the inhibitor changed its original binding conformation 
and aligned itself in the catalytic dyad. The active site pocket achieved an open conformation while 
PDB 
ID Compound
Amino acid resi-
dues in H-bond
Amino acids residues 
in antifungal proteins
1FI4 Wortmannin SER-258
THR262, SER258, 
MSE255, VAL229, 
LEU221
Voriconazole ALA303
ASP205, ALA303, 
GLY304, ASP201, GLY 
112, SER 207
1S4N Wortmannin SER382,TYR380
SER382, TYR380, 
HIS379, ILE378, 
LEU431, GLN429
Pyridobenzimidazole SER382
ASP383, HIS379, 
GLU396, TYR426, 
LEU431, SER382
3A58 Wortmannin ASN106,CYS93
GLU103, ASP98, 
CYS93, LYS100, 
ASN106
Nikkomycin ARG96,CYS93
ARG96, PRO105, 
GLU103, ASP98, 
ILE166, CYS92, ASP98
Table 6.  Predicted amino acid residues in protein templates using molecular docking methods.
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the inhibitor further buried itself in the catalytic dyad. This resulted in enhanced interaction of statine 
moiety with Ala 303 and brought about slight closing of the active site cleft (Fig. 4c), that conformation 
failed to attain stability and remained unstable for the rest of the simulation. However, for Wtmn, the 
binding conformation of the inhibitor forced the active site to remain in a closed conformation for most 
of the period. Still, around 250 ps the inhibitor realigned itself in the catalytic dyad further closed the 
active site to attain very tight binding conformation, and this conformation remained stable for rest of 
the simulation (Fig. 4a).
In the present in silico study, molecular docking and molecular dynamics approaches were applied 
to study the binding conformations and structural specificity of the antifungal inhibitors. Voriconazole 
and pyridobenzimidazole compounds demonstrated similar binding orientations with general specificity 
towards the catalytic dyad of the enzyme. Pyridobenzimidazole anchored more steadily into the cata-
lytic dyad by having more hydrogen bonding pairs between the enzyme and the inhibitor. Moreover, in 
computational studies, Wtmn showed better binding and greater specificity than the other two antifun-
gal compounds, which have the ability to anchor both catalytic dyad residues and flap residues thereby 
maintaining a tightly closed conformation throughout the simulation period, which indicated greater 
specificity towards the structure of the enzyme. Our in silico study explores structural specificity of all the 
three inhibitors towards the available protein structures and provides valuable insight into designing of 
highly specific inhibitors towards antifungal enzyme. Overall, Wtmn demonstrated promising antifungal 
results and future studies related to experimental validation of predicted target(s) through enzyme assay 
could provide excellent leads for highly selective inhibitors for antifungal enzyme. Currently, our group 
and collaborators are aggressively engaged in over-expression and nano-particle drug delivery related 
studies of Wtmn to address the issues of enhanced-economic production, toxicity reduction and stability 
enhancement.
In conclusion we can say the production of Wtmn from P. radicum has been reported for the very 
first time in this report. The antifungal activity of Wtmn was re-confirmed using various fungal strains 
and it was found that Wtmn showed excellent antifungal activity in addition to its previously known 
anti-cancerous activity. In silico docking showed that the isolated Wtmn was capable of binding efficiently 
with various predicted fungal targets, like, 1FI4, 3A58 and 1S4N. Lower docking energies of Wtmn (1FI4: 
− 7.69; 1S4N: − 8.86; 3A58: − 6.70) and presence of active amino acid residues (SER258 of 1FI4; SER 
382, TYR380 of 1S4N and ASN106, CYS93 of 3A58) during its interaction with the predicted targets 
suggested that Wtmn works more efficiently than the commercially available antifungal drugs (voricona-
zole and nikkomycin) used in this computational study. Our in-vitro and in- silico findings suggest that 
Wtmn produced from P. radicum is a promising lead compound which could be potentially used as an 
efficient antifungal drug in humans after appropriate structural modifications to reduce toxicity and 
improve stability.
Methods
Isolation, characterization and fermentation conditions of microorganism. A fungal strain 
designated as SF, was isolated from the pre-treated soil sample collected from agricultural field of 
Figure 3. Docked conformations of Inhibitors in Red (AutoDock) and Green (FlexiDock) with respect 
to crystal structure ligand in blue. (a) Wortmannin (b) Voriconazole (c) Pyridobenzimidazole.
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northern India [Geographical specifications: District- Faizabad, Uttar Pradesh, India (Latitude 26° 47’ N; 
Longitude 82° 12’ E)]. For the collection of soil sample no specific permissions were required for these 
locations/ activities and the performed field studies did not involve endangered or protected species. 
The strain was maintained on agar slants containing (g/L) dextrose 40, mycological peptone 10 and agar 
20 (pH 7–7.2). The isolated strain was characterized morphologically and biochemically following the 
protocol given by Shirling and Gottlieb36, and Holt et al.37. Finally, the isolated strain was identified by 
18S rRNA sequence homology.
Submerged fermentation was carried out in various production media [i.e., potato dextrose broth 
(PDB), sabouraud dextrose broth (SDB), czapekdox broth (CB), synthetic broth (SB) etc.] in Erlenmeyer 
flasks. Fermented broth from PDB showed maximum zone of inhibition against Candida albicans ATCC 
24433 and considered as the most suitable medium for metabolite production (data not shown), and 
used as the production medium for further studies. Fermentation was carried out by inoculating the 
production medium with 1.0% (v/v) of 48 h old seed inoculums of the producer strain and incubating 
the flasks at 28 °C; 180 rpm for 120 h.
Figure 4. Root mean squared deviations (RMSD) between - (a) Wortmannin and backbone atoms of 
Protein structure (PDB ID: 1S4N) (b) Pyridobenzimidazole and backbone atoms of Protein structure (PDB 
ID: 1FI4) (c) Voriconazole and backbone atoms of Protein structure (PDB ID: 3A58).
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Purification and chemical characterization of the active compound. Biomass was separated 
from the fermented culture by centrifuging it at 11,110xg for 20 min. The supernatant was extracted 
with chloroform and the organic layer containing active metabolites was collected and evaporated under 
reduced pressure. The residue was purified by silica gel (mesh size: 230–400) column chromatography 
using increasing gradient of methanol-chloroform (0–50%) as an elutant. The collected fractions were 
tested for antifungal activity by disc diffusion method against Candida albicans ATCC 24433. The frac-
tions showing similar antifungal activity were pooled together and again subjected to silica gel column 
chromatography using mesh size 230–400. Purity of the fractions showing significant antifungal activity 
was further examined by high pressure liquid chromatography (HPLC) using analytical C-18 silica col-
umn (Lachrom) at a flow rate of 1 ml/min with Merck system at 254 nm. Finally the chemical structure 
of the compound was established with the help of UV (Perkin Elmer Lambda- 25 UV spectrophotome-
ter), IR (FT-IR Perkin Elmer RX-1 spectrometer), ESMS (Micromass Quattro II triple quadrupole mass 
spectrometer) and 1H and 13C NMR spectra (600 MHz VARIAN INOVA instrument).
Bioactivity of the purified compound. (a) Antifungal activity. Antifungal activity of the purified 
compound was quantitatively determined in terms of minimum inhibitory concentration (MIC) employ-
ing broth dilution method using 200 μ g/ml as a starting concentration of the compound. MICs of the 
purified compound were studied with serial dilution method as recommended by the NCCLS guide-
lines38.
(b) Cytotoxic activity. Cytotoxic activity of the purified compound was evaluated using in-vitro MTT 
colorimetric assay against four human tumor cell lines (HEP-2 liver cells; IMR-32 neuroblastoma; HCT-
15 and 502713 colon carcinoma cells) according to the methodology given by Mossman39.
In-silico antifungal target site prediction. The in-silico studies were performed for the target site 
prediction for antifungal activity.
(a) Preparation of receptor. The crystal structures of the known potent antifungal drug targets were 
obtained from the Protein Data Bank (PDB)40. Analysis for number of missing atoms, removal of water 
molecules to clean the crystal structure and addition of H-atoms to these target proteins for correct ioniza-
tion and tautomeric states of amino acid residues in three structures viz. 1FI4 (mevalonate-5-diphosphate 
decarboxylase), 1S4N (Glycolipid 2-alpha mannosyltransferase), 3A58 (exocyst complex component 
SEC3) were analysed for certain modifications which made them suitable for molecular docking. The 
energy was minimized for these protein structures using Gromacs software program (version 4.0) 
[Gromacs User Manual, Version 4.0 (2005); www.gromacs.org] in steepest descent followed by conju-
gate gradient method and all these minimization steps were performed using Gromos 87 force field41.
(b) Ligand preparation. The two-dimensional (2D) structures of ligand molecules or compounds 
(Wtmn, voriconazole, nikkomycin, pyridobenzimidazole) used in the present study have been shown 
in Table  4. The 2D structure of above mentioned compounds were retrieved from NCBI PubChem 
database and converted into 3D structures employing SYBYL X. The geometrics of these compounds 
were optimized using Merck Molecular Force Field (MMFF) and Gasteiger-Marsili Charge with 10,000 
PDB 
ID Inhibitors
Docking energy 
AutoDock (Kcal/
mol)
Docking energy 
FlexiDock (Kcal/
mol) Active site residues
1FI4 Wortmannin − 7.69 − 697.214 Ser 258
Voriconazole − 5.73 − 505.913 Ala 303
Nikkomycin − 6.27 − 498.682 Arg 96
Pyriobenzimidazole − 10.24 − 712.429 Ser 382
1S4N Wortmannin − 8.99 − 358.968 Ser 358
Voriconazole − 9.20 − 412.359 Ala 303, Asp205
Nikkomycin − 8.92 − 406.322 Arg 96, Cys 93
Pyriobenzimidazole − 22.36 − 908.254 Ser 382, Asp 383
3A58 Wortmannin − 6.70 − 294.647 Asp 214, Val 78
Voriconazole − 6.34 − 532.144 Asp 34,Val 78
Nikkomycin − 5.89 − 438.214 Asp 214,Ser 218
Pyriobenzimidazole − 8.41 − 798.385 Asp 383, Asp 383
Table 7.  Comparative docking energies (AutoDock & FlexiDock) of antifungal drugs and their 
interaction with the active site.
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as maximum number of cycles, 0.01 as convergence criteria (root mean square gradient) and 1.0 as con-
stant (medium’s dielectric constant which is 1 for in vacuo) in dielectric properties. The default values 
of electrostatic as 20.0, vdW as 10.0 and vdW after iterations as 10 Kcal/mol were used for non-bonded 
cut-off implemented in VLife MDS 1.0 (http://www.vlifesciences.com).
(c) Molecular docking set-up. The molecular docking studies were performed using open source software 
(AutoDock 4.2) and licensed version (FlexiDock) available in SYBYL. AutoDock combines energy eval-
uation through pre-calculated grids of affinity potential employing various search algorithms to find the 
suitable binding position for a ligand on a given protein42. Kollman united atom charges and polar hydro-
gens were added to the receptor PDB using AutoDock tools42. All rotatable bonds in the ligands were 
kept free to allow for flexible docking. Binding site for the ligand was chosen around Thr-262 and Ser-258 
side chain which included all amino acid residues in the active site. Grid size was set to 60 × 60 × 60 
grid points (x, y and z), with spacing between the grid points kept at 0.375 Å. The Lamarckian genetic 
algorithm was chosen for searching the best conformers. The standard docking protocol was applied 
which is based on the population size of 150 randomly placed individuals, a maximum number of 250000 
energy evaluations, a mutation rate of 0.02, a crossover rate of 0.80 and an elitism value of 1. Twenty five 
independent docking runs were carried out for each inhibitor and cluster tolerance was kept at 1.0 Å. The 
best docking conformers from each class of ligand were further verified using FlexiDock available from 
SYBYL-X, each FlexiDock simulation was performed with 25,000 generations. Binding site was defined 
around 3 Å region of previously docked ligand, the resulting conformations from FlexiDock runs were 
compared with AutoDock to establish veracity of AutoDock runs.
(d) Molecular dynamics set-up. Based upon the molecular docking outcomes, molecular dynamics sim-
ulations of active site enzyme- inhibitor complexes were carried out using Gromacs 4.2 suite of programs 
(www.gromacs.org) using AMBER 94 force field (www.ambermd.org). Each of the complexes comprising 
the active site was placed in the centre of 60*60*60 Ǻ cubic box and solvated by SPC/E water molecules41. 
The gromacs topology file for ligands was generated using the PRODRG2 server. The time constant for 
Berendsen temperature coupling and Berendsen pressure coupling were both set at 0.1. The molecu-
lar dynamics method was done at a constant temperature and pressure of 300 K and 1 bar. All of the 
complexes were energy minimized using steepest descent method. Further, a 30 ps position restraining 
simulation was carried out to restrict the movement of the protein in the simulation. For the long range 
electrostatic interactions, Particle Mesh Ewald (PME) electrostatic was used. The cut-off for coulomb 
interactions and Van der Waal interactions were set to 1.0 nm and 1.4 nm, respectively. The LINCS algo-
rithm was employed for all the bond constraints.
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